Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation by Eckman Mark H, Rosand Jonathan, Greenberg Steven M, Gage Brian F in Annals of internal medicine (2009). PubMed

Abstract

Variants in genes involved in warfarin metabolism and sensitivity affect individual warfarin requirements and the risk for bleeding. Testing for these variant alleles might allow more personalized dosing of warfarin during the induction phase. In 2007, the U.S. Food and Drug Administration changed the labeling for warfarin (Coumadin, Bristol-Myers Squibb, Princeton, New Jersey), suggesting that clinicians consider genetic testing before initiating therapy.

[ hide abstract ]

Discussed In Paper

Related In Paper

Variant Annotations

None.